Overview

A Study of the Dosing, Efficacy, and Safety of Oral Cysteamine in Adult Patients With Cystic Fibrosis Exacerbations

Status:
Completed
Trial end date:
2018-04-01
Target enrollment:
Participant gender:
Summary
This study investigates the use of cysteamine in the treatment of adults with Cystic Fibrosis who are experiencing an exacerbation of CF-associated lung disease. There are six different potential dosing regimens, including one that is placebo.
Phase:
Phase 2
Details
Lead Sponsor:
NovaBiotics Ltd.
Collaborators:
Agility Clinical, Inc.
PSR Group B.V.
Treatments:
Cysteamine